Iproteos is biotechnology a company based in Barcelona, Spain. The company focuses its activity on the Research and Development of new therapeutic strategies based on peptidic protease inhibition. At Iproteos we are developing peptidic protease inhibitors for the treatment of CNS diseases. Our business model implies discovering, pre-clinical validation, patenting and licensing new peptide drugs. The drug development is driven by a dedicated team of experts and strategy advisors.
Recent News
Iproteos selected as finalist of the BIOCHEM Business Plan Competition
Iproteos has been selected as one of the finalists presenting their business project at the BIOCHEM Accelerator Forum, which takes place next June in Frankfurt during the ACHEMA 2012 fair in the frame of the BiobasedWorld http://www.biochem-project.eu/index.php?page=accelerator/frankfurt
Iproteos in the news
Iproteos founder Prof. Ernest Giralt receives the National Research Award 2011
Recent Events
Iproteos at the 7th International Symposium on Neuroprotection and Neurorepair
Iproteos is present at the 7th International Symposium on Neuroprotection and Neurorepair 2012 in Potsdam (Germany) from May 2nd to May 5th, joining experts in the field of stroke as well as Parkinson’s and Alzheimer’s disease to discuss recent scientific … Continue reading
4th EFMC Short Courses on Medicinal Chemistry – Safety and attrition workshop
Europeptides 2011, November 15-16
 |
 |
 |
 |